| CAS NO: | 5428-80-8 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 425.78 |
|---|---|
| Formula | C21H21ClN2O · 2HCl |
| CAS No. | 5428-80-8 (free base) |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 70 mg/mL (164.4 mM) |
| Water: <1 mg/mL | |
| Ethanol: <1 mg/mL | |
| Solubility (In vivo) | ClC1=CC=C(C2=NC(C=CC=C3)=C3C(C(O)C4NCCCC4)=C2)C=C1.[H]Cl |
| Synonyms | NSC13316 hydrochloride; NSC 13316; NSC-13316; Vacquinol-1; Vacquinol 1; Vacquinol1 hydrochloride |
| In Vitro | In vitro activity: Vacquinol-1 induces rapid and specific cell death of glioma cells with IC50 of 3.14 μM via membrane ruffling, cell rounding, massive macropinocytic vacuole accumulation, ATP depletion, and cytoplasmic membrane rupture. Kinase Assay: Vacquinol-1 (also known as NSC-13316; NSC13316) is an MKK4 (mitogen-activated protein kinase kinase 4) activator with antitumor activity. Cell Assay: Cell viability is measured using CellTiter-Glo Luminescent Cell Viability Assay according to the manufacturer’s instructions. |
|---|---|
| In Vivo | The ability of vacquinol-1 to attenuate tumor progression was previously tested in a mouse model for human GBM. Vacquinol-1 or vehicle (DMSO) were intracranially administered into the site of original cell deposit 6 weeks after engraftment. Results showed that tumors were invariantly smaller, and the area of necrosis and hGFAP and hNestin immunoreactivity was significantly reduced. Moreove, only tumor cells in vacquinol-1-treated mice showed a massive LAMP1 staining. |
| Animal model | Mice bearing U3013MG tumors |
| Formulation & Dosage | Dissolved in DMSO; 15 μM or 20 mg/kg; Intracranial injection, i.p., p.o. |
| References | Cell. 2014 Apr 10;157(2):313-28. |
m.cnreagent.com